Screening for hereditary haemochromatosis

Pathology

Volumn 44, Issue 2, 2012, Pages 148-152

  Nadakkavukaran, Itty M ^a   Gan, Eng K ^a,b   Olynyk, John K ^a,b,c,d  

^a FREMANTLE HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d CURTIN UNIVERSITY   (Australia)

Author keywords

C282Y mutation; Haemochromatosis; Hereditary; Screening

Indexed keywords

EID: 84858314194     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32834e8453     Document Type: Article

References (52)

1. Olynyk JK, Trinder D, Ramm GA, et al. Hereditary hemochromatosis in the post-HFE era. Hepatology 2008; 48: 991-1001.
2. Beutler E, Gelbart T, West C, et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis 1996; 22: 187-94. (Pubitemid 26397324)
3. Bacon BR, Olynyk JK, Brunt EM, et al. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med 1999; 130: 953-62. (Pubitemid 29283985)
4. Burt MJ, Smit DJ, Pyper WR, et al. A 4.5-megabase YAC contig and physical map over the hemochromatosis gene region. Genomics 1996; 33: 153-8. (Pubitemid 26132553)
5. Olynyk JK, Cullen DJ, Aquilia S, et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999; 341: 718-24. (Pubitemid 29407371)
6. Adams LA, Angulo P, Abraham SC, et al. The effect of the metabolic syndrome, hepatic steatosis and steatohepatitis on liver fibrosis in hereditary hemochromatosis. Liver Int 2006; 26: 298-304 (Pubitemid 43349319)
7. Delatycki MB, Allen KJ, Nisselle AE, et al. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet 2005; 366: 314-6. (Pubitemid 41019421)
8. Barton JC, Rao SV, Pereira NM, et al. Juvenile hemochromatosis in the southeastern United States: a report of seven cases in two kinships. Blood Cells Mol Dis 2002; 29: 104-15.
9. Beaton M, Guyader D, Deugnier Y, et al. Noninvasive prediction of cirrhosis in C282Y-linked hemochromatosis. Hepatology 2002; 36: 673-8. (Pubitemid 34977178)
10. Asberg A, Hveem K, Thorstensen K, et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 2001; 36: 1108-15. (Pubitemid 32801699)
11. Gan EK, Ayonrinde OT, Trinder D, et al. Phenotypic expression of hereditary hemochromatosis: what have we learned from the population studies? Curr Gastroenterol Rep 2010; 12: 7-12.
12. Gan EK, Powell LW, Olynyk JK. Natural history and management of HFE Hemochromatosis. Semin Liver Dis 2011; 31: 293-301.
13. Olynyk JK, Hagan SE, Cullen DJ, et al. Evolution of untreated hereditary hemochromatosis in the Busselton population: A 17-year study. Mayo Clin Proc 2004; 79: 309-13. (Pubitemid 38269232)
14. Andersen RV, Tybjaerg-Hansen A, Appleyard M, et al. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 2004; 103: 2914-9. (Pubitemid 38451659)
15. Whitlock EP, Garlitz BA, Harris EL, et al. Screening for hereditary hemochromatosis: a systematic review for the US Preventive Services Task Force. Ann Intern Med 2006; 145: 209-23. (Pubitemid 46780566)
16. Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008; 358: 221-30.
17. Gurrin LC, Bertalli NA, Dalton GW, et al. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology 2009; 50: 94-101.
18. Gurrin LC, Osborne NJ, Constantine CC, et al. The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gastroenterology 2008; 135: 1945-52.
19. Allen KJ. Population genetic screening for hereditary haemochromatosis: are we a step closer? Med J Aust 2008; 189: 300-1.
20. Gan EK, Trinder D, Ayonrinde OT, et al. Genetics of hereditary hemo-chromatosis: a clinical perspective. Expert Rev Endocrinol Metab 2009; 4: 225-39.
21. Olynyk JK, Gan E, Tan T. Predicting iron overload in hyperferritinemia. Clin Gastroenterol H 2009; 7: 359-62.
22. Ferrari P, Kulkarni H, Dheda S, et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 77-83.
23. St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005; 105: 855-61. (Pubitemid 40070775)
24. Allen KJ, Bertali NA, Osborne NJ, et al. HFE C282Tyr homozygotes with serum ferritin concentrations below 1000 mg/L are at low risk of hemo-chromatosis. Hepatology 2010; 52: 925-33.
25. Carroll GJ, Breidahl WH, Bulsara MK, et al. Hereditary hemochromatosis is characterized by a clinically definable arthropathy that correlates with iron load. Arthritis Rheum 2011; 63: 286-94.
26. Guyader D, Jacquelinet C, Moirand R, et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 1998; 115: 929-36. (Pubitemid 28452941)
27. Powell LW, Dixon JL, Ramm GA, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006; 166: 294-301. (Pubitemid 43244317)
28. Milward EA, Trinder D, Wilcox CE, et al. Is HFE involved in increased hepcidin expression and hypoferremia in inflammation and anemia of chronic disease? Hepatology 2005; 41: 936-8. (Pubitemid 40462956)
29. Shi Z, Johnstone D, Talseth B, et al. Haemochromatosis HFE gene polymorphisms as potential modifiers of hereditary nonpolyposis colorectal cancer risk and onset age. Int J Cancer 2009; 125: 78-83.
30. Osborne NJ, Gurrin LC, Allen KJ, et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology 2010; 51: 1311-8.
31. Gunel-Ozcan A, Alyilmaz-Bekmez S, Guler EN, et al. HFE H63D mutation frequency shows an increase in Turkish women with breast cancer. BMC Cancer 2006; 6: 37.
32. Zacharski LR, Chow BK, Howes PS, et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008; 100: 996-1002. (Pubitemid 352019800)
33. Rossi E, Olynyk JK, Cullen DJ, et al. Compound heterozygous hemo-chromatosis genotype predicts increased iron and erythrocyte indices in women. Clin Chem 2000; 46: 162-6. (Pubitemid 30104238)
34. Wilson JM, Jungner YG. Principles and practice of mass screening for disease. (Spanish). Bol Oficina Sanit Panam 1968; 65: 281-393.
35. Davis W, Arrowsmith W. The effect of repeated phlebotomies in hemo-chromatosis-Report of 3 cases. J Lab Clin Med 1952; 39: 526.
36. Bismuth M,Peynaud-Debayle E. Management of patients with HFE-related haemochromatosis (Type 1 haemochromatosis). 2005 (cited 10 Mar 2011). http://www.has-sante.fr/portail/jcms/c-432802/management-of-patients-with-hfe- related-haemochromatosis-type-1-haemochromatosis.
37. Brissot P, de Bels F. Current approaches to the management of hemo-chromatosis. Hematology Am Soc Hematol Educ Program 2006:36-41.
38. Adams PC, Barton JC. Haemochromatosis. Lancet 2007; 370: 1855-60. (Pubitemid 350180034)
39. European Association for the Study of the Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010; 53:3-22.
40. Tavill AS. Diagnosis and management of hemochromatosis. Hepatology 2001; 33: 1321-8. (Pubitemid 32378233)
41. Barton JC, Bottomley SS. Iron deficiency due to excessive therapeutic phlebotomy in hemochromatosis. Am J Hematol 2000; 65: 223-6.
42. Niederau C, Fischer R, Purschel A, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110: 1107-19. (Pubitemid 26113751)
43. Davis W, Arrowsmith W. The treatment of Hemochromatosis by massive venesection. Ann Intern Med 1953; 39: 723-34.
44. Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985; 313: 1256-62. (Pubitemid 16217048)
45. Adams PC, Speechley M, Kertesz AE. Long-term survival analysis in hereditary hemochromatosis. Gastroenterology 1991; 101: 368-72.
46. Bomford A, Williams R. Long-term results of venesection therapy in idiopathic hemochromatosis. Q J Med 1976; 45: 611-23.
47. Phatak PD, Bonkovsky HL, Kowdley KV. Hereditary hemochromatosis: time for targeted screening. Ann Intern Med 2008; 149: 270-2.
48. Gagne G, Reinharz D, Laflamme N, et al. Hereditary hemochromatosis screening: effect of mutation penetrance and prevalence on cost-effectiveness of testing algorithms. Clin Genet 2007; 71: 46-58. (Pubitemid 44921621)
49. Rogowski WH. The cost-effectiveness of screening for hereditary hemo-chromatosis in Germany: a remodeling study. Med Decis Making 2009; 29: 224-38.
50. Krawczak M, Cooper DN, Schmidtke J. Estimating the efficacy and efficiency of cascade genetic screening. Am J Hum Genet 2001; 69: 361-70. (Pubitemid 32695208)
51. Galhenage SP, Viiala CH, Olynyk JK. Screening for hemochromatosis: patients with liver disease, families, and populations. Curr Gastroenterol Rep 2004; 6: 44-51. (Pubitemid 39359584)
52. Davis TM, Beilby J, Davis WA, et al. Prevalence, characteristics, and prognostic significance of HFE gene mutations in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2008; 31: 1795-801